Welcome to our dedicated page for Science 37 Holdings news (Ticker: SNCE), a resource for investors and traders seeking the latest updates and insights on Science 37 Holdings stock.
Science 37 Holdings, Inc. (Nasdaq: SNCE) is a pioneering company based in Los Angeles that specializes in accelerating biomedical discovery through innovative, patient-centric clinical research models. Utilizing cutting-edge telemedicine technology, Science 37 offers a comprehensive range of services for conducting networked clinical trials, making it an invaluable partner for investigators, inventors, biotech firms, and large pharmaceutical companies.
At the core of Science 37's operations is the Metasite™, a proprietary virtual site platform that allows patients to participate in clinical trials from the comfort of their own homes or local healthcare providers. Powered by in-house medical and operational experts, the Metasite™ ensures uniform study orchestration, greater compliance, and high-quality data, thereby making clinical trials more accessible and efficient.
Science 37 leverages a vast network of partnerships with national mobile nursing companies, pharmacy chains, patient advocacy groups, and technology companies to streamline the clinical trial process. The company's recent achievements include the successful completion of a reverse stock split and a partnership with leading telemedicine companies, which has significantly expanded its reach and capabilities.
Noteworthy recent developments include the approval of a reverse stock split to comply with Nasdaq listing requirements and the commencement of a cash tender offer by eMed to purchase all outstanding shares of Science 37 at $5.75 per share. This move, coupled with the company's continuous efforts in enhancing patient recruitment through AI-powered screening and centralized processes, underscores its commitment to innovation and operational excellence.
Science 37 has also been recognized for its transformative impact on clinical research, winning the “Clinical Efficiency Innovation Award” at the 8th annual MedTech Breakthrough Awards. This award highlights the company's unique approach to patient recruitment, which has significantly improved patient randomization rates and site satisfaction.
For more detailed information and to stay updated on the latest developments, please visit Science 37's website.
Science 37 Holdings, Inc. (Nasdaq: SNCE) has announced a multi-year partnership with Amazon Web Services (AWS) to enhance the adoption and scaling of its Metasite platform, which allows clinical trial sponsors to engage patients beyond traditional sites. This collaboration aims to leverage AWS's robust analytics, security, and machine learning capabilities to expedite trial processes and improve patient safety. The partnership is set to expand Science 37's customer reach and support patient recruitment efforts. AWS's involvement is expected to modernize clinical research, leading to quicker trial enrollment and fostering diverse patient populations.
Science 37 Holdings, Inc. (Nasdaq: SNCE) has appointed Irena Lambridis as its new Global Head of Quality Assurance & Compliance, aiming to enhance the company's quality oversight as it expands globally across its new Centers of Excellence in India, Pakistan, and Slovakia.
Irena brings nearly 20 years of clinical research quality assurance experience, previously holding leadership roles at KCR and Novella Clinical, now part of IQVIA Biotech. Her expertise will help ensure adherence to quality standards and regulatory compliance.
This appointment aligns with Science 37's mission to lead in quality within the decentralized clinical trials (DCT) industry and supports its goal of accelerating patient access to clinical research.
FAQ
What is the market cap of Science 37 Holdings (SNCE)?
What does Science 37 Holdings, Inc. specialize in?
What is the Metasite™?
What recent financial developments have occurred at Science 37?
What awards has Science 37 won recently?
How does Science 37 enhance patient recruitment for clinical trials?
Who are Science 37's main partners?
Where is Science 37 headquartered?
What is the aim of Science 37's clinical research models?
What is the significance of the reverse stock split for Science 37?
How can I learn more about Science 37's active studies?
